147 related articles for article (PubMed ID: 37718465)
21. Local recurrence and cerebral progression-free survival after multiple sessions of stereotactic radiotherapy of brain metastases: a retrospective study of 184 patients : Statistical analysis.
Kuntz L; Le Fèvre C; Jarnet D; Keller A; Meyer P; Bund C; Chambrelant I; Antoni D; Noel G
Strahlenther Onkol; 2022 Jun; 198(6):527-536. PubMed ID: 35294567
[TBL] [Abstract][Full Text] [Related]
22. Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases.
Enright TL; Witt JS; Burr AR; Yadav P; Leal T; Baschnagel AM
Clin Lung Cancer; 2021 Mar; 22(2):110-119. PubMed ID: 33281062
[TBL] [Abstract][Full Text] [Related]
23. Single fraction stereotactic radiosurgery and fractionated stereotactic radiotherapy provide equal prognosis with overall survival in patients with brain metastases at diagnosis without surgery at primary site.
Ostdiek-Wille GP; Amin S; Wang S; Zhang C; Lin C
PeerJ; 2023; 11():e15357. PubMed ID: 37223122
[TBL] [Abstract][Full Text] [Related]
24. Overall survival after initial radiotherapy for brain metastases; a population based study of 2140 patients with non-small cell lung cancer.
Karlsson AT; Hjermstad MJ; Omdahl T; Aass N; Skovlund E; Hellebust TP; Johansen S; Kaasa S; Yri OE
Acta Oncol; 2021 Aug; 60(8):1054-1060. PubMed ID: 34032536
[TBL] [Abstract][Full Text] [Related]
25. Large intracranial metastatic tumors treated by Gamma Knife surgery: outcomes and prognostic factors.
Lee CC; Yen CP; Xu Z; Schlesinger D; Sheehan J
J Neurosurg; 2014 Jan; 120(1):52-9. PubMed ID: 24160478
[TBL] [Abstract][Full Text] [Related]
26. A new strategy of CyberKnife treatment system based radiosurgery followed by early use of adjuvant bevacizumab treatment for brain metastasis with extensive cerebral edema.
Wang Y; Wang E; Pan L; Dai J; Zhang N; Wang X; Liu X; Mei G; Sheng X
J Neurooncol; 2014 Sep; 119(2):369-76. PubMed ID: 24879376
[TBL] [Abstract][Full Text] [Related]
27. Peritumoral Brain Edema in Metastases May Be Related to Glymphatic Dysfunction.
Toh CH; Siow TY; Castillo M
Front Oncol; 2021; 11():725354. PubMed ID: 34722268
[TBL] [Abstract][Full Text] [Related]
28. Role of perilesional edema and tumor volume in the prognosis of non-small cell lung cancer (NSCLC) undergoing radiosurgery (SRS) for brain metastases.
Nardone V; Nanni S; Pastina P; Vinciguerra C; Cerase A; Correale P; Guida C; Giordano A; Tini P; Reginelli A; Cappabianca S; Pirtoli L
Strahlenther Onkol; 2019 Aug; 195(8):734-744. PubMed ID: 31123785
[TBL] [Abstract][Full Text] [Related]
29. Whole-brain radiotherapy combined with surgery or stereotactic radiotherapy in patients with brain oligometastases: long-term analysis.
D'Agostino GR; Autorino R; Pompucci A; De Santis MC; Manfrida S; Di Lella G; Mantini G; Frascino V; Chiesa S; Albanese A; Dinapoli N; Azario L; Fiorentino A; Valentini V; Anile C; Balducci M
Strahlenther Onkol; 2011 Jul; 187(7):421-5. PubMed ID: 21713390
[TBL] [Abstract][Full Text] [Related]
30. The efficacy of stereotactic radiotherapy for metastases from renal cell carcinoma.
Majewski W; Tabor M; Banaszek P; Glowacki G; Rokicki W; Tukiendorf A
Neoplasma; 2016; 63(1):99-106. PubMed ID: 26639239
[TBL] [Abstract][Full Text] [Related]
31. Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer.
Yang RF; Yu B; Zhang RQ; Wang XH; Li C; Wang P; Zhang Y; Han B; Gao XX; Zhang L; Jiang ZM
Braz J Med Biol Res; 2017 Nov; 51(1):e6073. PubMed ID: 29185589
[TBL] [Abstract][Full Text] [Related]
32. PACS-Integrated Tools for Peritumoral Edema Volumetrics Provide Additional Information to RANO-BM-Based Assessment of Lung Cancer Brain Metastases after Stereotactic Radiotherapy: A Pilot Study.
Kaur M; Cassinelli Petersen G; Jekel L; von Reppert M; Varghese S; Dixe de Oliveira Santo I; Avesta A; Aneja S; Omuro A; Chiang V; Aboian M
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835516
[TBL] [Abstract][Full Text] [Related]
33. Effect of bevacizumab against cystic components of brain tumors.
Yamasaki F; Kolakshyapati M; Takano M; Yonezawa U; Nishibuchi I; Imano N; Taguchi A; Onishi S; Amatya VJ; Takeshima Y; Nagata Y; Kurisu K; Sugiyama K
Cancer Med; 2019 Nov; 8(15):6519-6527. PubMed ID: 31498567
[TBL] [Abstract][Full Text] [Related]
34. Fifty percent patients avoid whole brain radiotherapy: stereotactic radiotherapy for multiple brain metastases: a retrospective analysis of a single center.
Chen X; Xiao J; Li X; Jiang X; Zhang Y; Xu Y; Dai J
Clin Transl Oncol; 2012 Aug; 14(8):599-605. PubMed ID: 22855144
[TBL] [Abstract][Full Text] [Related]
35. Interfractional target changes in brain metastases during 13-fraction stereotactic radiotherapy.
Uto M; Ogura K; Katagiri T; Takehana K; Mizowaki T
Radiat Oncol; 2021 Jul; 16(1):140. PubMed ID: 34321033
[TBL] [Abstract][Full Text] [Related]
36. Toxicity and time lapse between immunotherapy and stereotactic radiotherapy of brain metastases.
Cabanie C; Biau J; Durando X; Mansard S; Molnar I; Chassin V; Verrelle P; Khalil T; Lapeyre M; Dupic G
Cancer Radiother; 2021 Jul; 25(5):432-440. PubMed ID: 33836954
[TBL] [Abstract][Full Text] [Related]
37. Tumor-related venous obstruction and development of peritumoral brain edema in meningiomas.
Bitzer M; Topka H; Morgalla M; Friese S; Wöckel L; Voigt K
Neurosurgery; 1998 Apr; 42(4):730-7. PubMed ID: 9574636
[TBL] [Abstract][Full Text] [Related]
38. Poor performance status and brain metastases treatment: who may benefit from the stereotactic radiotherapy?
Holub K; Louvel G
J Neurooncol; 2021 Apr; 152(2):383-393. PubMed ID: 33590401
[TBL] [Abstract][Full Text] [Related]
39. Survival after surgery and stereotactic radiosurgery for patients with multiple intracranial metastases: results of a single-center retrospective study.
Smith TR; Lall RR; Lall RR; Abecassis IJ; Arnaout OM; Marymont MH; Swanson KR; Chandler JP
J Neurosurg; 2014 Oct; 121(4):839-45. PubMed ID: 24857242
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of Stereotactic Radiotherapy and Bevacizumab for Recurrent High-Grade Gliomas: A Potential Therapy for Isocitrate Dehydrogenase Wild-Type Recurrent High-Grade Gliomas.
Yasuda T; Muragaki Y; Nitta M; Miyamoto K; Oura Y; Henmi T; Noguchi S; Oda H; Saito T; Maruyama T; Atsuchi S; Miura N; Kawamata T
World Neurosurg; 2018 Jun; 114():e1138-e1146. PubMed ID: 29614360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
